X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licensing to commercially manufacture Oral Polio Vaccines in India.
Lead Product(s): Live, Attenuated Polio Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: BIOPOLIO B1/3
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bilthoven Biologicals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 02, 2024
Details:
Mtbvac, the spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis, which is under clinical development for the treatment of tuberculosis in adults.
Lead Product(s): Mtbvac
Therapeutic Area: Infections and Infectious Diseases Product Name: Mtbvac
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biofabri
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2024
Details:
iNCOVACC (Chad SARS-COV-2) is a novel adenovirus vectored, intranasal vaccine for COVID-19. It stimulates a broad immune response such as neutralizing IgG, mucosal IgA, and T cell responses at the site of infection (in the nasal mucosa).
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: iNCOVACC
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2023
Details:
iNCOVACC® (BBV154), is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and as a heterologous booster dose. iNCOVACC® is stable at 2-8C for easy storage and distribution.
Lead Product(s): BBV154
Therapeutic Area: Infections and Infectious Diseases Product Name: iNCOVACC
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
iNCOVACC, An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.Immune responses at the site of infection (in the nasal mucosa)–essential for blocking both infection and transmission of COVID-19.
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: iNCOVACC
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
BBV152 (Covaxin), is a beta-propiolactone inactivated vaccine, India’s indigenous response to fighting the SARS-CoV-2 pandemic for the treatment of coronavirus disease.
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2022
Details:
The COVID-19 vaccine candidate BBV152, known as COVAXIN™, is a whole-virion inactivated COVID-19 vaccine candidate that applies the same vero cell manufacturing platform used in the production of polio vaccines for decades.
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Ocugen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
iNCOVACC (Chad SARS-COV-2) is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein in those aged 18 to 5 years.
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: iNCOVACC
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by CDSCO for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
Lead Product(s): ChAd36-SARS-CoV-S
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Being an intranasal vaccine, BBV154 (Chad SARS-COV-2), may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission.
Lead Product(s): Chad SARS-COV-2
Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
